Company Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Country | United States |
| IPO Date | May 3, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Howard W. Robin |
Contact Details
Address: 455 Mission Bay Boulevard South San Francisco, California 94158 United States | |
| Phone | (415) 482-5300 |
| Website | nektar.com |
Stock Details
| Ticker Symbol | NKTR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000906709 |
| CUSIP Number | 640268108 |
| ISIN Number | US6402681083 |
| Employer ID | 94-3134940 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Howard W. Robin | Chief Executive Officer, President and Director |
| Mark A. Wilson | Senior Vice President, Chief Legal Officer and Secretary |
| Dr. Jonathan Zalevsky Ph.D. | Chief Research and Development Officer |
| Sandra A. Gardiner | Interim Chief Financial Officer |
| Vivian Wu | Director of Investor Relations and Corporate Affairs |
| Robert Bacci | Senior Vice President of Human Resources and Facilities Operations |
| Jennifer Ruddock | Chief Business Officer |
| Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K | Current Report |
| Mar 19, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 5, 2024 | 10-K | Annual Report |
| Mar 4, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 144 | Filing |
| Feb 20, 2024 | 144 | Filing |
| Feb 20, 2024 | 144 | Filing |
| Feb 16, 2024 | 8-K | Current Report |